In a phase I/II clinical trial, a promising result showed a new drug targeting common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC). The drug also targets a form of the mutation that causes resistance to treatment.
The research will be presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Approximately 10-15% of Caucasian and 30-35% of Asian patients with NSCLC have a mutation in the epidermal ...
In a phase I/II clinical trial, a promising result showed a new drug targeting common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC). The drug also targets a form of the mutation that causes resistance to treatment.
The research will be presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
Approximately 10-15% of Caucasian and 30-35% of Asian patients with NSCLC have a mutation in the epidermal ...